SCHEMBL985990

SCHEMBL985990

Nc1cnc2[nH]c(Nc3ccccc3)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.50
KMT2A Q03164 5/20 0.50
RIPK1 Q13546 1/20 0.43
EGFR P00533 3/20 0.42
MAPT P10636 4/20 0.42
KDM4E B2RXH2 2/20 0.42
BCL6 P41182 2/20 0.41
AKR1C3 P42330 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PIM1 P11309 1/20 0.40
TAAR1 Q96RJ0 2/20 0.40
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
GSK3B P49841 1/20 0.39
CSNK1G2 P78368 1/20 0.39
LMNA P02545 2/20 0.39
GAA P10253 2/20 0.39
GFER P55789 2/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3026523 0.78 MEN1 (0.45) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL1663100 0.77 MEN1 (0.68) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL987289 0.76 RIPK1 (0.63) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL986878 0.75 ALDH1A1 (0.54) MEN1KMT2AMAPTKDM4ERAB9A
SCHEMBL1663106 0.74 MEN1 (0.68) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL32666102 0.72 MAPT (0.61) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL32666096 0.71 MEN1 (0.59) MEN1KMT2ARIPK1EGFRMAPT
SCHEMBL8573943 0.69 MEN1 (0.53) MEN1KMT2ARIPK1MAPTKDM4E
SCHEMBL30020996 0.68 MEN1 (0.75) MEN1KMT2ARIPK1MAPTAKR1C3
SCHEMBL239690 0.68 MEN1 (0.75) MEN1KMT2ARIPK1MAPTAKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265609-B1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC (US) 2012-09-05 EP disclosed
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. 2011-01-06 US disclosed
EP-2265609-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS Array Biopharma, Inc. (US) 2010-12-29 EP disclosed
WO-2009111277-A9 IMIDAZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-12-30 WO disclosed
WO-2009111277-A1 IMDIZO [4. 5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-09-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003809-A1 IMIDAZO [4,5-B] PYRIDINE DERIVATIVES USED AS RAF INHIBITORS BRAF, RAF1, ARAF MEN1 1673/4885KMT2A 2318/4885RIPK1 894/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.